Abstract
Bone morphogenetic proteins (BMPs) represent a family of differentiation factors that promote bone formation and remodeling. Clinical use of recombinant BMP was approved by the US Food and Drug Administration (FDA) in 2002 for surgery of the anterior lumbar spine to promote bone fusion. Due to robust bone forming properties, BMP use may increase the likelihood of bony fusion thereby decreasing the undesired outcome of pseudarthrosis or nonunion.
Highlights
Bone morphogenetic proteins (BMPs) represent a family of differentiation factors that promote bone formation and remodeling [1]
Clinical use of recombinant BMP was approved by the US Food and Drug Administration (FDA) in 2002 for surgery of the anterior lumbar spine to promote bone fusion [2]
Two BMP products are commercially available for clinical use, one of which is rhBMP-2, known as INFUSE. (MedtronicSofamorDanek, Memphis, Tennessee)
Summary
Bone morphogenetic proteins (BMPs) represent a family of differentiation factors that promote bone formation and remodeling [1]. Extubation Airway Emergency after Spinal Fusion Using Bone Morphogenetic Protein *Corresponding author: Bradley J Scherer, MD, Department of Pediatrics, Riley Hospital for Children at Indiana University Health, Indiana University School of Medicine, 705 Riley Hospital Drive, Room 5900, Indianapolis, IN 46202-5225, USA, Tel: +317-944-7337, E-mail: bjschere@iupui.edu
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
